{"id":29511,"date":"2025-03-17T17:03:55","date_gmt":"2025-03-17T09:03:55","guid":{"rendered":"https:\/\/flcube.com\/?p=29511"},"modified":"2025-03-17T17:03:57","modified_gmt":"2025-03-17T09:03:57","slug":"accropeutics-closes-rmb100-million-series-b-round-to-advance-inflammatory-disease-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=29511","title":{"rendered":"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline"},"content":{"rendered":"\n<p>Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and Hefei Innovation Scitech Venture Capital. The funds will be used to accelerate clinical development of drugs targeting various inflammatory and autoimmune diseases.<\/p>\n\n\n\n<p><strong>Product Pipeline and Clinical Development<\/strong><br>Accropeutics&#8217; product pipeline includes several promising candidates:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AC-101<\/strong>, an RIPK2 inhibitor developed from Accropeutics&#8217; &#8220;regulatory cell death and inflammation&#8221;-targeted R&amp;D platform, is being developed to treat inflammatory bowel disease (IBD). It is currently undergoing a Phase Ib study in ulcerative colitis (UC) in China and received approval for trials in the US last December.<\/li>\n\n\n\n<li><strong>AC-201<\/strong>, a TYK2\/JAK1 inhibitor, is nearing the completion of Phase II studies in moderate to severe plaque psoriasis in Australia and China.<\/li>\n\n\n\n<li><strong>AC-003<\/strong>, a RIPK1 inhibitor, is undergoing Phase Ib studies in acute graft-versus-host disease (aGVHD) in the US and China.<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Focus<\/strong><br>The proceeds from this financing round will be dedicated to advancing the clinical development of these and other candidates in Accropeutics&#8217; pipeline, with a focus on addressing significant unmet medical needs in inflammatory and autoimmune diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":29513,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2772,65,20],"class_list":["post-29511","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-accropeutics","tag-auto-immune","tag-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and Hefei Innovation Scitech Venture Capital. The funds will be used to accelerate clinical development of drugs targeting various inflammatory and autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=29511\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline\" \/>\n<meta property=\"og:description\" content=\"Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and Hefei Innovation Scitech Venture Capital. The funds will be used to accelerate clinical development of drugs targeting various inflammatory and autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=29511\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-17T09:03:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-17T09:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1710-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline\",\"datePublished\":\"2025-03-17T09:03:55+00:00\",\"dateModified\":\"2025-03-17T09:03:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1710-png.avif\",\"keywords\":[\"Accropeutics\",\"Auto-immune\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29511#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=29511\",\"name\":\"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1710-png.avif\",\"datePublished\":\"2025-03-17T09:03:55+00:00\",\"dateModified\":\"2025-03-17T09:03:57+00:00\",\"description\":\"Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and Hefei Innovation Scitech Venture Capital. The funds will be used to accelerate clinical development of drugs targeting various inflammatory and autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29511\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1710-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1710-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29511#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and Hefei Innovation Scitech Venture Capital. The funds will be used to accelerate clinical development of drugs targeting various inflammatory and autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=29511","og_locale":"en_US","og_type":"article","og_title":"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline","og_description":"Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and Hefei Innovation Scitech Venture Capital. The funds will be used to accelerate clinical development of drugs targeting various inflammatory and autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=29511","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-17T09:03:55+00:00","article_modified_time":"2025-03-17T09:03:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1710-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=29511#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=29511"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline","datePublished":"2025-03-17T09:03:55+00:00","dateModified":"2025-03-17T09:03:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=29511"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=29511#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1710-png.avif","keywords":["Accropeutics","Auto-immune","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=29511#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=29511","url":"https:\/\/flcube.com\/?p=29511","name":"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=29511#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=29511#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1710-png.avif","datePublished":"2025-03-17T09:03:55+00:00","dateModified":"2025-03-17T09:03:57+00:00","description":"Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and Hefei Innovation Scitech Venture Capital. The funds will be used to accelerate clinical development of drugs targeting various inflammatory and autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=29511#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=29511"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=29511#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1710-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1710-png.avif","width":1080,"height":608,"caption":"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=29511#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1710-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29511"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29511\/revisions"}],"predecessor-version":[{"id":29514,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29511\/revisions\/29514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/29513"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}